SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...

Researchers, university tech transfer offices, pharmaceutical companies, and disease-focused philanthropic organizations often face a challenge in translating academic research projects into viable licensing candidates or start-up companies. Pappas Translational Medicine works hands-on with our partners to help identify, catalyze and manage those projects that have the best chance to become market-ready.
We target life science technologies and platforms with high potential to reach private-sector transaction-enabling milestones—with the goal of expanding the pipeline of high quality translational medicine programs.